Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced the successful completion of a pilot project with Kuano Ltd. that supports advancement of the company’s PNKP Inhibitor Technology (ONC010) through AI-enabled and quantum-based computational analysis. Kuano delivered molecular modeling and computational findings that strengthened Onco’s understanding of how its PNKP inhibitor and related analogs may interact with the target, producing a refined structural hypothesis for PNKP inhibition and establishing a framework for structure-based optimization and future evaluation.
The project also applied quantum-based computational methods to assess PNKP structural behavior and develop human PNKP structural models for follow-on analysis. According to the company, the results are expected to support future initiatives including quantum-based QSAR modeling, toxicity mapping and AI-assisted generative compound design, with the goal of improving compound prioritization and accelerating progress toward preclinical development. This announcement is significant as it demonstrates the integration of cutting-edge technologies like artificial intelligence and quantum computing into oncology drug discovery, potentially reducing the time and cost of developing new cancer therapies.
The implications of this pilot are far-reaching. By leveraging AI and quantum computing, Onco-Innovations aims to enhance the precision of its drug design, which could lead to more effective PNKP inhibitors for treating solid tumors. The refined structural hypothesis and human PNKP models provide a foundation for subsequent research and development activities. Investors and stakeholders should note that the company has secured an exclusive worldwide license to patented technology targeting solid tumors, underscoring its commitment to pioneering cancer research. For more details on the press release, visit https://ibn.fm/SdQqD.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF. This development highlights the potential of computational approaches in modern drug discovery, setting the stage for more efficient and targeted cancer treatments.